Abstract
In this triple analysis report BioSeeker Group has analyzed three major and
intertwined areas of cancer R&D, Lymphoma, Protein Kinase Inhibitors and
Therapeutic Antibodies, which are all subjects to an extensive number of
innovative drug candidates. This extensive 320 pages report compiles and
analyzes the progress concerning drug development and competitive situation in
the three mentioned key oncology areas. The report will not only provide a
framework but also a careful identification and evaluation of drug candidates,
technologies and competitors
Published trial data show an increase in response rates when rituximab is
combined with current chemotherapy regimens in both the first- and second-
line settings in the treatment of lymphoma. In addition, rituximab show
significant off-label usage. Already today it is clear that rituximab has
generated substantial revenues for the companies involved in its development.
A collection of emerging facts suggest that several of the new targeted
therapies under development include agents that cannot just be added into
treatment regimens with conventional drugs. A few of them might have isolated
properties on certain biologic targets that may require to be modulated in
particular ways before or after cytotoxic chemotherapy. Among the emerging
therapeutic strategies, passive and active immunotherapies have clearly
continued to be leading strategies. Small molecule kinase inhibitors are as
well in the forefront
The commercial and therapeutic success of antibodies will force the industry
to look into the next generation of therapeutic antibodies, preparing
themselves for the second wave in the lucrative field of therapeutic
antibodies. The first-generation formulations of therapeutic antibodies will
be facing heavy competition from biogeneric companies as their profitable
antibody drugs comes off patent in the future. Among the different strategies
(e.g., antibody engineering, changes in primary structure, fusions, chemical
modifications glycosylation, pegylation, polymer conjugates), the approach of
miniaturizing and delivering antibody drugs is the most promising because it
permits better release of active drugs.
The number of protein kinase inhibitor drugs has risen sharply, as the number
of targets. The fiercest competition in kinase inhibitor drug development is
found in hematological, breast, lung, prostate, and colorectal cancer. Several
big pharma companies are out hunting for promising technology and drugs to
complement their internal pipeline.
View Cart
